In the past few years, immune-checkpoint inhibitors which target immune-checkpoint pathways including cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and PD-1/PD-L1 have been developed in advanced ovarian cancer [16]. Here, CTLA4 is linked to ovarian cancer.